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Background: Microspherule protein 1 (MCRS1) is a candidate oncogene and participates in various cellular processes,
including growth, migration, senescence and transformation. MCRS1 is overexpressed in non-small cell lung cancer
(NSCLC) and promotes the growth of cancer cells. However, the mechanisms driving these processes are not
fully understood.
Methods: Retrovirus-mediated RNA interference was employed to knockdown MCRS1 expression in cell lines.
Cell proliferation assays and animal experiments were respectively performed to evaluate the growth of NSCLC cells
in vitro and in vivo. Microarray analysis was carried out for mRNA profiling. Luciferase reporter assay and microRNA
(miRNA) transfection were used to investigate the interaction between miRNA and gene.
Results: Stably knocking down MCRS1 expression inhibited the proliferation of NSCLC cells in vitro and in vivo. By
comparing the mRNA expression profiles of NSCLC cells with or without MCRS1 silencing, we found that MCRS1
regulated expressions of various genes related to cell proliferation, including Rb1, TP53, cell cycle-related genes, MYC,
E2F2, PCNA, and Ki67. However, MCRS1 did not directly bind to these differentially expressed genes. Here, we confirmed
that Rb1, an important tumor suppression gene (TSG), is a direct target of miR-155 which is directly up-regulated by
MCRS1. Furthermore, the level of Rb1 expression in NSCLC tissues was inversely correlated with those of miR-155 and
MCRS1, and MCRS1 regulated expression of Rb1 via miR-155. Additionally, we found that the DNA copy number of the
MCRS1 gene played a role in MCRS1 overexpression in NSCLCs.
Conclusion: MCRS1 overexpression induced NSCLC proliferation through the miR-155–Rb1 pathway and DNA copy-
number amplification is one of the mechanisms underlying MCRS1 overexpression in NSCLC. Moreover, we put forward
the hypothesis that there are regulatory relationships between oncogenes and TSGs apart from the functional synergy of
both; the oncogene-miRNA-TSG networks are one of mechanisms among the regulatory relationships; the regulatory
relationships and the networks might play active roles in the development and progression of cancer.
Keywords: Lung cancer, MCRS1, miR-155, Rb1, Proliferation, DNA copy numberBackground
Lung cancer is the leading cause of cancer-related death
in the world. Lung cancer can be divided into small-cell
lung cancers and non-small cell lung cancers (NSCLCs),
the latter of which account for more than 80 % of all types
of lung cancer, including adenocarcinomas (ACs), squa-
mous cell carcinomas (SCCs) and large-cell carcinomas* Correspondence: caoy@mail.kiz.ac.cn
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involving the accumulation of genetic and epigenetic alter-
ations, resulting in uncontrolled proliferation, cellular
transformation and the acquisition of aggressive behavior.
Although much effort has been invested in identifying the
genes related to lung cancer, the mechanisms underlying
this disease are not fully understood.
In previous studies, we screened novel lung cancer-
related genes using a combination of cytogenetic and
molecular genetic methods and found that microspher-
ule protein 1 (MCRS1) was overexpressed in NSCLCsistributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Liu et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:121 Page 2 of 12[1, 2]. Furthermore, abnormal expression of MCRS1 was
found to be correlated with cellular proliferation, the
epithelial-mesenchymal transition (EMT) and metastasis,
implying that MCRS1 may play critical roles in lung
tumorigenesis [2, 3]. MCRS1, also known as p78 and
MSP58, was initially identified as an interacting partner
of the proliferation-related nucleolar protein p120 and
was localized to the nucleolus [4]. Consistent with its
nucleolar location, MCRS1 was found to mediate dis-
tinct cellular functions through interactions with various
proteins present in this organelle, including nucleolar
proteins, transcription factors and RNA-binding proteins
[4–9]. In previous studies, a small fraction of p78/
MCRS1 was found to co-localize with centrosomal pro-
teins, such as Nde1 and DIPA, suggesting that MCRS1
plays a role in centrosomal homeostasis [10, 11]. Notably,
MCRS1 exhibited transformative properties in fibroblast
cells, whereas the PTEN tumor suppressor inhibited this
transformative property [12, 13]. Moreover, MCRS1 silen-
cing was reported to suppress the proliferation, migration
and invasion of the tumor cells of other types of can-
cers [14–17]. Based on the transformative properties
of MCRS1 and its biological roles in various types of
human cancers, MCRS1 can be considered a candi-
date oncogene. However, the mechanism(s) underlying
the enhanced expression of MCRS1 and the conse-
quences of its aberrant regulation are not fully under-
stood. In the present study, we investigated the effect
of MCRS1 on the proliferation of NSCLC cells




NSCLC and adjacent non-tumor lung tissues were ob-
tained from patients during surgery in Kunming Medical
University. The study was approved by the Ethics Com-
mittee for Human Medicine Research, Kunming Institute
of Zoology, Chinese Academy of Sciences (Permit Num-
ber: SYDW-2012010). Written informed consent was ob-
tained from the patients before obtaining samples for this
study.
The animal experiments were carried out in strict ac-
cordance with the guidelines and approved by the Ethics
Committee for Animal Experimentation, Kunming Insti-
tute of Zoology (Permit Number: SYDW-2012010).
NSCLC tissue samples and cell lines
Samples of primary NSCLC tissues were obtained from
30 patients during surgery. None of the patients had
been treated before undergoing surgery. All of these
samples were diagnosed according to the classification
system of the World Health Organization and were
staged using the criteria of the International UnionAgainst Cancer [18, 19]. Samples of ten lung tissues,
which were obtained from patients with lung bullous
disease and lung inflammatory pseudotumors who were
undergoing surgery, were used as the “noncancerous tis-
sues.” The clinical characteristics of patients are listed in
Additional file 1.
The lung cancer cell lines EPLC-32M1 (SCC), A549
(AC), 801D (LCC), NCIH-292 (mucoepidermoid carcin-
oma), NCI-H460 (LCC) and 16HBE (immortalized human
bronchial epithelial cells) have been described previ-
ously [2, 3]. And details of all cell lines were provided
in Additional file 2.
Generation of stable subcellular MCRS1 knockdown lines
The MCRS1 silencing vector was previously described [2].
A target sequence (GCTGAAGAACAACGGTGAT) was
designed and produced for MCRS1 silencing, and a
luciferase-targeting shRNA oligonucleotide was used as the
negative control. The complementary strands of the oligo-
nucleotides were annealed and were ligated into the preli-
nearized RNAi-Ready pSIREN-RetroQ vector (Clontech,
Palo Alto, CA, USA). The MCRS1-silencing and negative
control vectors were transfected into RetroPack PT-67 cells
using Lipofectamine 2000 reagent (Invitrogen, Carlsbad,
CA, USA). Forty-eight hours after transfection, the
retrovirus-containing medium was filtered, and the retrovi-
ruses were used to infect the cells of NSCLC lines in the
presence of 10 μg/ml Polybrene (Sigma, St. Louis, MO,
USA). Forty-eight hours after infection, the cells were se-
lected using puromycin (Sigma).
Oligonucleotide transfection
The miR-155 mimics, 2′-O-methylated miRNA anti-
sense oligonucleotides (ASO) and their cognate con-
trols that were used for transient transfection, were
purchased from the RiBoBio Company (Guangzhou,
China). Transfection was performed using Lipofectamine
2000 (Invitrogen) according to the manufacturer’s instruc-
tions. In each case, 100 nmol/L of the miRNA mimic and
150 nmol/L of the ASO were used.
Vector construction
To generate the Rb1 (retinoblastoma-related gene 1) lu-
ciferase reporter plasmid (pGL-Rb1), the 3′ untranslated
region (3′-UTR) encompassing the miR-155 binding site
was cloned between the KpnI and XhoI restriction sites
of the pGL-3 basic vector (Promega, Madison, WI, USA)
using a Polymerase Chain Reaction (PCR)-generated
fragment. The mutation in the miR-155 binding site of
the human Rb1 3′-UTR was generated using overlapping
PCR. For the ectopic expression of Rb1, the coding region
of human Rb1 was cloned into the pCDH-CMV-
MCS-EF1-GFP-T2A-Puro vector (System Biosciences,
California, USA). Subsequently, virus packaging and
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instructions. The contents of all of these constructs
were confirmed by sequencing. The primers used are
shown in Additional file 3.
MiRNA target prediction and luciferase reporter assays
The miRWalk database was used to predict the target
genes of miRNAs [20]. The genes that had both down-
regulated expression after MCRS1 silencing and had
been predicted to be targets of miR-155 were chosen for
analysis using the reporter assay.
Each reporter construct and the Renilla luciferase
expression plasmid (pRL-TK) was co-transfected into
cells with the miR-155 mimic or its negative control
using Lipofectamine 2000. The pRL-TK plasmid was
used as an internal control. Forty-eight hours after trans-
fection, the levels of luciferase activity were determined
using the Dual-Luciferase Reporter System (Promega)
according to the manufacturer’s instructions.
Quantitative real-time polymerase chain reaction
(QRT-PCR) assays of miRNA and mRNA expression
The total RNA was extracted from cells and tissues using
TRIzol reagent (Sigma). The qRT-PCR assays of mRNA
and miRNA expression levels were conducted as previ-
ously described [3]. The housekeeping genes GAPDH and
U6 snRNA were used as internal controls for the mRNA
and miRNA assays, respectively. The primers used are
shown in Additional file 3.
Western blotting analysis
The preparation of protein-containing lysates and west-
ern blotting was conducted as described previously [3].
Briefly, the proteins in the lysates were resolved using
10 % sodium dodecylsulfate polyacrylamide gel electro-
phoresis (SDS-PAGE) and were transferred to PVDF
membranes (Millipore, Bedford, MA, USA). The mem-
branes were incubated with the following antibodies:
anti-Rb1 (sc-50; Santa Cruz Biotechnology Inc., Santa
Cruz, CA, USA), anti-MCRS1 (R36649; Sigma), and
anti-GAPDH (G8795; Sigma). Finally, the membrane
was incubated with SuperSignal West Pico chemilu-
minescent substrate (Thermo Fisher Scientific Inc.,
Waltham, MA, USA), and the blots were exposed to
X-ray film. The films were developed, scanned and
analyzed using the Image J software (NIH, Bethesda,
MD, USA). GAPDH was used as an internal control.
MTT assay
Cells were seeded at a density of 4 × 103 cells/well in
96-well plates. Seventy-two hours post-transfection,
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) was added to each well. After an incubation
period, the medium was removed, and dimethyl sulfoxide(DMSO) was added. The absorbance at 570 nm (using
630 nm as a reference) was detected using a microplate
reader (model 680, Bio-Rad Laboratories, Berkeley,
CA, USA).In vivo tumor growth assay
Sixteen female BALB/c nude mice (4 weeks old) were
purchased from Vital River Laboratories (Beijing, China)
and were housed under standard conditions. Overall,
1 × 106 control EPLC-32 M1 cells (without MCRS1 si-
lencing) and MCRS1-knockdown EPLC-32 M1 cells
were subcutaneously implanted into the left and right
flanks of the same mouse, respectively. Tumor growth
was assessed using calipers every five days from 4 days
to 32 days post-implantation, and the tumor volumes
were estimated using the following equation: 0.5 ×
length × width2. The mice were anesthetized with diethyl
ether and sacrificed by cervical dislocation at 5 weeks
post-implantation, and the tumor pairs were harvested
and weighed.cDNA microarray analysis
The total RNA was extracted from MCRS1 knock-
downed cells and control cells using TRIzol reagent
(Sigma). Agilent 60 K Human Gene Expression arrays
were used for mRNA profiling. Quality control of the total
RNA, the probe labeling, and the array hybridization, as
well as the data extraction and normalization, were per-
formed at the CapitalBio Corporation (Beijing, China;
http://www.capitalbio.com). The differentially expressed
genes were determined according to the ratio of their
expression levels relative to those of the control cells
(ratio > 2: upregulated genes; ratio < 0.5: downregu-
lated genes). The differentially expressed genes are
shown in Additional file 4.Chromatin immunoprecipitation (ChIP) assays
The ChIP assays were performed using the EZ-Magna
ChIP kit (Millipore, Merck KGaA, Darmstadt, Germany)
as described previously [3]. Briefly, the chromatin of the
samples was sheared into fragments with an average
length of approximately 250 bp by sonication on ice
using a Bioruptor sonicator. Immunoprecipitation of the
sonicated chromatin fragments was conducted using an
anti-MCRS1 antibody (SC-376569; Santa Cruz Biotech-
nology) and normal mouse IgG antibodies (the negative
control), and the input and immunoprecipitated DNA
fragments were analyzed using PCR. The GAPDH
promoter primers provided in the ChIP kit were used
as the internal control. The primers used are shown
in Additional file 3.
Liu et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:121 Page 4 of 12DNA copy number assays
Genomic DNA was extracted from tissues and cul-
tured cells using standard methods. After digesting
the samples using proteinase K, the genomic DNA
was isolated using phenol/chloroform/isoamyl alcohol
and ethanol precipitation. Then, based on the instruc-
tions of the qBiomarker Copy Number PCR assay kit,
each sample DNA was diluted to the same concentra-
tion and was amplified using qRT-PCR. The results
were analyzed using the qBiomarker Data Analysis
program (http://pcrdataanalysis.sabiosciences.com/cnv/
CNVanalysis.php). The DNA copy number was deter-
mined using the 2-△CT method. The primer set used
to determine the MCRS1 copy number was as fol-
lows: 5′CACCAGAAGGCTCACTCTTCA3′ and 5′
TGTCTGGTTGTCGAAGTCCGG3′. The qBiomarker
Multicopy Reference Assay (MRef, QIAGEN, Suzhou,
China) was used as the internal control.
Statistical analysis
The data are presented as the mean values ± standard
deviation (SD) as obtained from at least three independ-
ent experiments. The data were analyzed using the SPSS
(Statistical Package for the Social Sciences) 17.0 software
package (Chicago, IL, USA). The obtained data (levels of
mRNA, the results of the MTT assay the in vivo tumor
growth assay and the DNA copy numbers) were ana-
lyzed using Student’s t-test or a one-way ANOVA, as ap-
propriate. The relationships among the levels of miRNA
expression, alterations in the copy number and the levels
of gene expression were evaluated using Pearson’s cor-
relation coefficients. The level of significance was set at
0.05 for all tests.
Results
Reducing the level of MCRS1 attenuates the growth of
NSCLC cells in vitro and in vivo
To investigate the effect of MCRS1 on tumor forma-
tion, we stably reduced the level of MCRS1 expres-
sion using RNA interference mediated by a retroviral
system (pSIREN-RetroQ) in EPLC-32 M1, A549 and
801D cells, representing SCC, AC and LCC cells, re-
spectively. The decreased level of MCRS1 expression
was assessed using qRT-PCR and western blotting as-
says (Fig. 1a).
The results of the cell proliferation assays showed that
MCRS1 silencing significantly decreased the rate of
NSCLC tumor cell proliferation in vitro (Fig. 1b). To fur-
ther study the effect of MCRS1 silencing on NSCLC
tumor formation in vivo, MCRS1-knockdown cells
(Msh3) and control cells (Luc) were subcutaneously
injected into the opposite flanks of nude mice (Fig. 1c).
Compared with the tumors derived from the control
cells, the tumors derived from the Msh3 cells displayeda significantly smaller size and mass (Figs. 1d-f ). Col-
lectively, the in vitro and in vivo analyses supported
the suppressive effect of MCRS1 silencing on tumor
cell growth, indicating that MCRS1 expression may
play a role in the growth of NSCLC cells.
MCRS1 knockdown induces the differential expression of
genes related to cellular proliferation
To explore the molecular mechanism(s) underlying
MCRS1-mediated cellular growth, we utilized a cDNA
microarray to determine the mRNA profiles of EPLC-
32 M1 cells with knocked-down MCRS1 expression. The
array data revealed that the expression levels of 369
genes were significantly altered after MCRS1 silencing.
Notably, among these altered genes, the levels of expres-
sion of the MYC oncogene and the genes for the prolif-
eration factor E2F2 and the proliferation markers Ki67
and PCNA were significantly downregulated. In contrast,
the levels of expression of the tumor suppressor genes
(TSG) TP53 and Rb1 were upregulated. Additionally, the
levels of expression of cell cycle-related genes, such as
Cyclin A2, Cyclin D1 and CDK4/6, were markedly chan-
ged (Fig. 2a). Subsequently, a qRT-PCR assay was used
to verify the levels of expressions of the genes listed in
Fig. 2a. Although the exact fold changes in the levels of
expression of these genes varied somewhat between the
data from the array and qRT-PCR, the data displayed
similar trends (Fig. 2b and c).
Considering that MCRS1 is involved in distinct cellu-
lar processes through activating various proteins, we fur-
ther sought to determine whether MCRS1 bound to
these genes, as shown in Fig. 2b and c. Regrettably, the
predictions obtained using the transcription factor bind-
ing site and promoter database suggested that the pro-
moter regions of these gene were not targets of MCRS1,
indicating that MCRS1 may regulate these genes via
other pathways, such as microRNA (miRNA)-based
pathways.
Taken together, these results indicated that MCRS1
could affect tumor cell growth through indirectly modu-
lating the expression of pro-proliferative, anti-proliferative
and cell cycle-related genes.
MCRS1 regulates cellular growth via miR-155 targeting of
the Rb1 gene
Our previous study demonstrated that miR-155 is a
downstream node of MCRS1 in lung cancer cells [3].
MCRS1 has been reported to regulate cellular prolifera-
tion and the cell cycle [16, 21, 22]. Based on this back-
ground, we attempted to determine whether MCRS1
modulates the proliferation of NSCLC cells via miR-155-
targeted genes. An integrated analysis of miR-155 target
prediction and verification of the microarray data using
qRT-PCR (Fig. 2b and c) indicated that the genes
Fig. 1 Stably knocking down the expression of MCRS1 inhibited the proliferation of NSCLC cells in vivo and in vitro. a The stable knockdown of MCRS1
expression decreased the levels of MCRS1 mRNA and protein in NSCLC cells compared with those of control cells without the MCRS1 knockdown. b The
stable knockdown of MCRS1 expression notably reduced the level of cell viability, as evaluated using an MTT assay. c A diagram of EPLC-32 M1 cells with
stably reduced MCRS1 expression and the control cells that were subcutaneously implanted into nude mice. d The stable knockdown of
MCRS1 expression significantly suppressed tumor growth in nude mice. The differences between MCRS1 knockdown cells and the matched control cells
were analyzed by Student’s t-test (P< 0.05). e Representative images of tumors at five weeks following the subcutaneous implantation of EPLC-32 M1
cells with or without MCRS1 knockdown in nude mice. f The stable knockdown of MCRS1 expression dramatically decreased the tumor weight relative
to that of tumors derived from control cells. Msh3: cells with knocked-down MCRS1 expression; Luc: cells without knocked-down MCRS1
expression. *P < 0.05 (Student’s t-test)
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Rb1 was chosen for further studies based on the follow-
ing two criteria: (1) Rb1 was predicted to be a target
gene of miR-155 (Fig. 3a) and plays a critical role in cel-
lular proliferation [23, 24]; and (2) Rb1 protein levels
were negatively correlated with miR-155 levels in lung
cancer tissues (Fig. 3b).
The forced expression of miR-155 greatly reduced the
level of Rb1 protein, and conversely, inhibiting miR-155
expression enhanced Rb1 protein expression in EPLC-
32 M1 and 801D cells (Fig. 3c, top panel), although the
Rb1 mRNA levels were not significantly different (Fig. 3c,
bottom). A luciferase reporter assay conducted using re-
porter gene constructs that contained the Rb1 3′ UTR
showed that the luminescence intensities were signifi-
cantly reduced following the addition of an miR-155
mimic. Furthermore, mutation of the putative miR-155
binding site in the Rb1 gene abrogated the repression ofluciferase activity caused by miR-155 overexpression
(Fig. 3d). To further confirm that the growth-promoting
effect of miR-155 was mediated by repressing Rb1 ex-
pression, a pCMV-Rb vector containing only the Rb1
coding sequence was constructed for the expression of
Rb1. As shown in Fig. 3e, the level of Rb1 was restored
after its exogenous expression via pCMV-Rb1. Add-
itionally, Rb1 re-expression effectively suppressed the
promotion of cellular proliferation caused by miR-155
overexpression (Fig. 3f). These results demonstrated that
Rb1 is a functional target of miR-155 in NSCLC cells.
Based on our previous study showing that miR-155 is a
downstream mediator of the function of MCRS1 in cellu-
lar proliferation and the EMT process [3], we examined
whether MCRS1 regulated tumor cell growth through
miR-155 targeting of the Rb1 gene. As shown in Fig. 3g,
Rb1 protein expression was downregulated in MCRS1-
overexpressing NSCLC tissues. In addition, the ectopic
Fig. 2 Genes related to cell proliferation that were differentially expressed upon knocked-down MCRS1 expression. a The results of an mRNA microarray
analysis of differentially expressed genes related to cell proliferation in EPLC-32 M1 cells in which the expression of MCRS1 was knocked
down. +, Upregulated; -, Downregulated. b and c qRT-PCR validation of the genes that were differentially expressed in EPLC-32 M1 and 801D cells with
(Msh3 cells) and without (Luc cells) the knocked-down expression of MCRS1. The results were analyzed using Student’s t-test (P < 0.05)
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of Rb1 protein in NSCLC cells with stably reduced
MCRS1 expression (Msh3 cells), whereas inhibiting miR-
155 expression partially restored the higher Rb1 level in
NSCLC control cells without MCRS1 silencing (Luc cells)
(Fig. 3h). In NSCLC samples, MCRS1 protein expression
showed positive and inversely correlation with miR-155
expression and Rb1 protein expression, respectively
(Additional file 5). Collectively, these data confirmed
that MCRS1 promotes the proliferation of NSCLC
cells via miR-155 targeting of the Rb1 gene.MCRS1 overexpression is partially caused by alterations
in gene copy number
Because alterations in the DNA copy number have a
dramatic impact on the level of gene expression, we next
assessed whether changes in the MCRS1 DNA copy
number contributed to the overexpression of MCRS1.
As shown in Fig. 4a, the DNA copy number and the level
of mRNA expression of MCRS1 were markedly elevated
in each cancer cell line compared with those of the 16HBE
cell line. Furthermore, the average DNA copy number of
MCRS1 was increased by approximately 1.5-fold in the
Fig. 3 MCRS1 regulated cellular proliferation via miR-155 targeting Rb1 mRNA in NSCLCs. a Schematic of the putative miR-155 binding site in the
Rb1 3′UTR region. b The results of the correlation analysis of the levels of miR-155 and Rb1 protein in NSCLC tissues (Pearson’s method,
R =−0.554, *P < 0.05). c Relative levels of expression of Rb1 protein (top) and Rb1 mRNA (bottom) in cells transfected with the miR-155
mimic, the NC mimic, an miR-155 inhibitor (miR-155 ASO) or NC ASO, respectively. (Student’s t-test, *P< 0.05). d Validation of the direct targeting of Rb1
mRNA by miR-155 was obtained using a luciferase reporter assay. WT: wild-type Rb1 3′UTR; MUT: mutant Rb1 3′UTR. (Student’s t-test, *P< 0.05). e The
inhibition of Rb1 expression by miR-155 was partially reversed by co-transfection with pCMV-Rb1 (to drive the ectopic expression of Rb1 mRNA lacking
the 3′UTR to which miR-155 bound) and the miR-155 mimic. f The level of cell viability was reduced by transfection with PCMV-Rb1. Importantly, the
induction of a higher level of cell viability by the miR-155 mimic was partially prevented by PCMV-Rb1 transfection. g The relative levels of expression of
Rb1 and MCRS1 protein in clinical samples. T: Tumor; N: Noncancerous. h The lower level of Rb1 protein in cancer cells without MCRS1 silencing (Luc)
was increased by treatment with the miR-155 inhibitor, and the higher level of Rb1 protein in the MCRS1-knockdown cells (Msh3) was decreased by
treatment with the miR-155 mimic. NC: negative control. ASO: antisense oligonucleotide
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Fig. 4 MCRS1 DNA copy numbers and MCRS1 mRNA expression levels. a Changes in the MCRS1 gene copy number and the level of MCRS1 mRNA
expression in cultured cells were evaluated using qRT-PCR. b The variation in the MCRS1 DNA copy number in the NSCLC tissues was compared with
that of noncancerous lung tissues. (Student’s t-test, *P < 0.05). c The results of the correlation analysis of the MCRS1 mRNA expression levels and the
MCRS1 copy number alterations. (Pearson’s method, R = 0.4, *P < 0.05)
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lung tissues (Fig. 4b). The statistical analysis revealed that
the DNA copy number was correlated with the level of
mRNA expression of MCRS1 (Fig. 4c). Moreover, statis-
tical analysis showed there are positive correlations be-
tween MCRS1 protein expression and MCRS1 copy
number, as well as MCRS1 protein expression and its
mRNA expression in NSCLC tissues (Additional file 6).
These data indicated that, at least in part, the MCRS1
gene copy number affected the expression levels of
MCRS1 mRNA and protein.
Discussion
MCRS1 has been reported to be associated with various
functions, such as transcriptional regulation and tel-
omerase inhibition and to be involved in cellular growth,
migration, senescence and transformation [5, 8, 9, 12,
13, 21, 22, 25]. Mounting evidence has demonstrated
that MCRS1 is overexpressed in human esophageal car-
cinomas, hepatocellular carcinomas and colorectal car-
cinomas [14–16]. In previous studies, we showed that
MCRS1 is abundantly expressed in NSCLCs [2, 3]. In
this study, downregulating MCRS1 expression signifi-
cantly inhibited the growth of tumor cells in vitro and in
an animal model.
Next, we clarified the mechanisms by which MCRS1
silencing inhibited tumor proliferation through compar-
ing the mRNA expression profiles of cultured lung can-
cer cells with or without MCRS1 silencing. The products
of the differentially expressed genes directly related to
cellular growth were grouped into the following families:
the JAK-STAT signaling pathway, the MAPK signaling
pathway, the mTOR signaling pathway, the p53 sig-
naling pathway, the pRb1/E2F cell-cycle pathway, and
the ErbB signaling pathway. Among the components
of these pathways with altered gene expression, severalmolecules associated with cellular proliferation are dis-
cussed below. 1) The expression of two classical TSG (P53
and Rb1) was upregulated at the mRNA level in NSCLC
cells with knocked-down MCRS1 expression. These two
genes have been universally accepted as playing important
roles in preventing the initiation and progression of
tumors [26–28]. In previous studies, downregulating
MCRS1 expression was found to increase the levels of
Rb1 and P21 expression in colorectal cancer cells [16],
whereas the ectopic expression of MCRS1 in normal hu-
man cells resulted in elevated protein levels of P53 and
P21 [22]. 2) The level of expression of the MYC gene was
noticeably downregulated following MCRS1 silencing.
MYC, which has been long considered to be an oncogene,
contributes to oncogenesis through overstimulating cellu-
lar growth and metabolism and cell cycle progression [29].
Although the bioinformatic predictions indicated that the
MYC gene was potentially regulated by the MCRS1 pro-
tein complex, chromatin immunoprecipitation (ChIP) as-
says revealed that MCRS1 and its complex did not
directly bind to MYC (Additional file 7). How MCRS1
affects MYC expression requires further investigation. 3)
The levels of vital cell cycle-related molecules (CDK4,
CDK6, cyclin A2 and cyclin D1) were remarkably altered
in the MCRS1 knockdown NSCLC cells, consistent with
previous observations that MCRS1 modulated cellular
proliferation through affecting cell cycle-related molecules
[9, 16, 21, 22]. 4) The level of E2F2, which plays critical
roles in cell cycle regulation and promoting cellular
growth [30], was reduced in lung cancer cells with
knocked-down MCRS1 levels. 5) As expected, the levels
of PCNA and Ki67, which are proliferation markers in
many types of human cancer, were decreased in NSCLC
cells after MCRS1 silencing. These results suggested that
MCRS1 promotes cellular growth through signaling path-
ways in which these molecules participate. Therefore, we
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and these signaling molecules in NSCLC. However, the re-
sults of the bioinformatic analyses and the ChIP assays
showed that MCRS1 did not bind to all of the genes en-
coding the molecules mentioned above, indicating that
MCRS1 may indirectly regulate the expression of these
genes through factors such as miRNAs.
Compelling evidence has demonstrated that miRNAs
are important regulators of gene transcription [31, 32].
Altered expressions of miRNAs are common events in
lung cancer [33]. Our previous study showed that MCRS1
binds to the promoter region of the miR-155 RNA host
gene (MIR155HG) and upregulates the expression of miR-
155 [3]. MiR-155 has been reported to act as an oncogenic
miRNA by promoting tumor growth, the EMT process
and invasion/metastasis [34–38]. Thus, we sought to
investigate whether MCRS1 promoted tumor growth
through miR-155-targeted genes. Firstly, the bioinformatic
analyses demonstrated that miR-155 can bind to Rb1
mRNA. Secondly, the level of Rb1 protein expression was
inversely correlated with that of miR-155 in lung cancer
tissues, which was consistent with the principle of the
miRNA-mediated regulation of mRNA expression (i.e.,
the general inverse relationship between the level of ex-
pression of a miRNA and those of its targets). Thirdly, we
transfected miR-155 mimics or inhibitors into NSCLC
cells and found that the forced expression of miR-155 re-
duced Rb1 levels and vice versa. Fourthly, the results of
the luciferase reporter assays revealed that miR-155 bound
to the 3′UTR of Rb1. Finally, a cellular functional assay
demonstrated that Rb1 overexpression partially abrogated
the positive effect of miR-155 on the growth of NSCLC
cells. Rb1 has been reported to function as a tumor sup-
pressor and to play critical roles in controlling the rate of
cellular growth and of tumorigenesis [23, 24]. Rb2, one of
Rb family members, is down-regulated in lung cancer
[39]. Here, our findings indicated that Rb1 is a functional
target of miR-155. Moreover, we confirmed the following
facts: 1) that the level of Rb1 protein expression was also
reversely correlated with that of MCRS1; 2) that the in-
crease in the level of Rb1 protein caused by MCRS1
knockdown was decreased by upregulating the level of
miR-155 in NSCLC cells, whereas decreasing the level of
Rb1 protein in the MCRS1 upregulated cells could be in-
creased by downregulating the expression of miR-155.
Collectively, these results indicated a new avenue for
the growth-promotion effect of MCRS1 on NSCLC
cells, which is conducted via the miR-155-Rb1 path-
way. Rb1 is one of the most important TSGs known.
An Rb1 mutation is associated with the development
of certain types of cancer [24]. Moreover, the data ob-
tained in this study indicated that apart from the Rb1 gen-
etic mutation, abnormal levels of MCRS1 and miR-155
also affected the expression and function of Rb1, therebycontributing to carcinogenesis. Our findings provide new
insights into the mechanisms regulating Rb1 expression.
Alterations in expressions and functions of oncogenes
and TSGs are considered as the major cause of carcino-
genesis. The functional synergy of oncogenes and TSGs
had been noticed. Interestingly, our study reveals an im-
portant fact that there are regulatory relationships be-
tween oncogenes and TSGs apart from the functional
synergy. Furthermore, we found that miRNA is one of
mediators between oncogene and TSG. In another re-
search, authors found that there is p53-miR-200-ZEB1/
BMI1 pathway and that the pathway regulates EMT and
stemness properties in breast cancer cells [40]. Thus, we
put forward the hypothesis that there are regulatory rela-
tionships between oncogenes and TSGs; the oncogene-
miRNA-TSG networks are one of mechanisms among
the regulatory relationships; the regulatory relationships
and the networks might play active roles in the develop-
ment and progression of cancer. Alterations in the gene
expression are involved in complex mechanisms includ-
ing genetic mutation, DNA copy number, transcription
factor, DNA methylation, histone modification, non-
coding RNA etc. The abnormal expressions of some on-
cogenes and TSGs in certain tumors have been eluci-
dated, however, the most mechanisms underlying the
abnormal expressions of oncogenes and TSGs in cancers
remains elusive. For examples, genetic mutations can
lead to loss or gain of gene functions, but loss or gain of
gene functions in some cancers are not caused by gen-
etic mutations, even their reasons are unclear up to
now. We speculate that the oncogene-miRNA-TSG net-
work may be an important regulator of the expressions
of oncogenes and TSGs in cancers apart from the clas-
sical mechanisms.
MCRS1 overexpression has been observed in human tu-
mors. In a previous study, we demonstrated that MCRS1
overexpression resulted partially from the downregulation
of the level of miR-129* in NSCLCs [3]. However, the mo-
lecular mechanisms underlying the alteration in MCRS1
expression were not entirely clear. Many studies have
shown that gene copy variation directly affected gene ex-
pression; for example, the DNA copy number of HER-2
and EGFR mediated the overexpression of these genes in
breast and lung cancer, respectively [41, 42]. In this study,
we analyzed the MCRS1 DNA copy number and found
that alterations in the MCRS1 DNA copy number were
consistent with the levels of MCRS1 mRNA and protein
observed; the MCRS1 DNA copy number in NSCLC tis-
sues and cultured lung cancer cells was dramatically ele-
vated compared with that in normal cells. We believe that
the MCRS1 DNA copy number affected the expression of
the MCRS1 gene to some extent. Additionally, we ana-
lyzed the results we obtained using whole-genome se-
quencing of 14 cases of NSCLC in another study [43] and
Liu et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:121 Page 10 of 12published the datasets obtained using NSCLC whole-
genome sequencing [44, 45], and we did not find any
MCRS1 gene mutations in the NSCLC samples. Accord-
ingly, changes in the MCRS1 DNA copy number may be a
mechanism underlying its overexpression in NSCLC cells,
but mutation of this gene is not necessary for its abnormal
regulation. Moreover, considering that the relationships
between the levels of MCRS1 and miR-155 as well as
those of miR-155 and Rb1, we explored whether an alter-
ation in the MCRS1 DNA copy number affected the ex-
pression of Rb1 and miR-155. Although there were
correlations between the MCRS1 DNA copy number and
the level of MCRS1 expression as well as between the
levels of MCRS1 and miR-155 expression, our data did
not demonstrate correlations between the MCRS1 DNA
copy number and the levels of Rb1 or miR-155 expression
(Additional file 8). These data indicated that factors other
than changes in the MCRS1 DNA copy number alsoFig. 5 Proposed model for MCRS1-mediated regulation of the proliferationregulated MCRS1 expression in NSCLC cells, e.g., the
level of miR-129* expression [3]. Similarly, factors other
than the levels of MCRS1 and miR-155 may also affect
Rb1 expression. The phenomena observed in this study
suggested that the regulatory mechanisms in effect and
the relationships between the levels of these molecules are
extremely complex in cancer cells and that their regula-
tion does not follow a single linear pattern but may rather
involve a network.
Conclusions
MCRS1 overexpression promoted the proliferation of
NSCLC cells and regulated their growth via various
pathways. In this study, we clearly demonstrated that
MCRS1 regulated the growth of NSCLC cells through
the miR-155-Rb1 pathway (Fig. 5). Additionally, MCRS1
overexpression was mediated by alterations in the DNA
copy number. MCRS1 is a candidate oncogene, and Rb1of NSCLC cells
Liu et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:121 Page 11 of 12is one of the most important tumor suppression genes.
We put forward the hypothesis that there are regulatory
relationships between oncogenes and TSGs apart from
the functional synergy of both; the oncogene-miRNA-
TSG networks are one of mechanisms among the regu-
latory relationships; the regulatory relationships and the
networks might play active roles in the development and
progression of cancer. Our study provides new insights
into the understanding of relationships between onco-
gene and TSG as well as abnormal expressions of onco-
genes and TSGs in cancers.Additional files
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